Effect of Preop and Postop ESP Block on Analgesia, Hemodynamics and Patient Satisfaction in Laparoscopic Cholecystectomy

NCT06670313 | Completed

• 1 other identifier: Sait
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Erector spinae plane (ESP) block is an interfascial plane block applied to the paraspinal region, which provides effective visceral and extensive somatic analgesia by providing paravertebral spread of the administered local anesthetic to three and four vertebral levels cranial and caudal. ESP block is a new regional anesthesia method applied with ultrasound (USG) guidance to provide analgesia for various surgeries and for acute or chronic pain. The application of this block is simple and can be performed in the preoperative waiting area with light sedation or no sedation. ESP block can be applied with a single injection or as a continuous infusion by catheter placement.

Conditions

Erector Spinae Plane Block

Outcome Measures

Primary Outcomes (1)

• primary outcome

  1\. Systolic arterial pressure,

  one day

Secondary Outcomes (1)

• Sevondary outcome

  one day

Study Arms (2)

Preop Erector spinae plane block

ACTIVE COMPARATOR

Patients who underwent erector spinae block before surgery

Other: postop Erector spinae plane block

postop Erector spinae plane block

ACTIVE COMPARATOR

Patients who underwent erector spinae block without waking the patient at the end of surgery

Other: postop Erector spinae plane block

Interventions

postop Erector spinae plane block OTHER

Postoperative ESP block was performed as the control group

Preop Erector spinae plane block; postop Erector spinae plane block

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• According to the physical classification of the American Society of Anesthesiologists (ASA), ASA I-II group,
• between the ages of 18-65,

You may not qualify if:

• Patients who do not want to participate in the study;
• BMI \>30,
• Patients with contraindications for ESP block,
• Uncooperative patients,
• Those with renal failure,
• Those with hepatic failure and
• ASA III-IV-V group patients

Sponsors & Collaborators

• Harran University: lead

Study Sites (1)

Veli Fahri Pehlivan

Sanliurfa, 63100, Turkey (Türkiye)

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Masking Details: Single-blind: Participants were blinded to group allocation.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: October 25, 2024
• First Posted: November 1, 2024
• Study Start: November 11, 2024
• Primary Completion: June 12, 2025
• Study Completion: June 25, 2025
• Last Updated: June 29, 2025

Record last verified: 2025-06

Locations

TU (1)